{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.7","upperLimit":"40.9","value":"24.0"},{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG001","lowerLimit":"17.1","upperLimit":"NA","value":"37.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"TNNT is defined as the number of days from the date of the first dose of venetoclax to the date of first dose of any non-protocol anti-leukemia therapy (NPT) or death from any cause. For participants who did not take NPT, their data was censored at the last known date to be free of NPT. TTNT was analyzed by Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG000","title":"ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts"},{"description":"Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG001","title":"ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts"}],"paramType":"MEDIAN","populationDescription":"All participants in the Main and Expansion Cohorts who received at least one dose of venetoclax","reportingStatus":"POSTED","timeFrame":"Collected every 3 months for a period of 5 years after the last participant had enrolled into the study","title":"Time to Next Anti-Chronic Lymphocytic Leukemia Treatment (TNNT)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}